1. Nucleoside reverse transcriptase inhibitors (NRTIs)

1.1. LAMIVUDINE (3TC) (PDF, 52K)

1.2. STAVUDINE (d4T) (PDF, 52K)

1.3. ZIDOVUDINE (AZT OR ZDV) (PDF, 60K)

1.4. ABACAVIR (ABC) (PDF, 55K)

1.5. DIDANOSINE (ddl) (PDF, 61K)

1.6. EMTRICITABINE (FTC) (PDF, 47K)

1.7. TENOFOVIR (TDF) (PDF, 47K)

2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

2.1. EFAVIRENZ (EFV) (PDF, 51K)

2.2. NEVIRAPINE (NVP) (PDF, 59K)

2.3. ETRAVIRINE (ETV) (PDF, 53K)

3. Protease inhibitors (PIs)

3.1. SAQUINAVIR (SQV) HGC (PDF, 47K)

3.2. LOPINAVIR/RITONAVIR (LPV/r) (CO-FORMULATION) (PDF, 56K)

3.3. RITONAVIR (RTV) (PDF, 48K)

3.4. DARUNAVIR (DRV) (PDF, 47K)

3.5. ATAZANAVIR (ATV) (PDF, 47K)

4. Fixed-dose combinations (FDCs)

Antiretroviral therapy generally requires the use of three or more drugs. This often requires taking a large number of tablets/capsules each day. Fixed-dose combinations (FDCs) of ARV drugs allow for once- or twice-daily dosing, leading to improved adherence, which may result in greater efficacy and may assist in reducing the development of viral resistance. FDCs are cheaper than individual drugs and may help to alleviate programmatic concerns of logistics regarding drug supply and delivery. WHO encourages the use of FDCs when formulations of assured quality and proven bioequivalence are available and offer operational advantages. Not all available FDCs have been evaluated for prequalification by WHO. Further details and a list of current prequalified drugs are available at: http://mednet3.who.int/prequal/.

Countries that have not included FDCs in their national formularies are encouraged to do so.

4.1. ZIDOVUDINE (AZT) PLUS LAMIVUDINE (3TC) (PDF, 51K)

4.2. ZIDOVUDINE (AZT) PLUS LAMIVUDINE (3TC) PLUS NEVIRAPINE (NVP) (PDF, 51K)

4.3. STAVUDINE (D4T) PLUS LAMIVUDINE (3TC) (PDF, 49K)

4.4. STAVUDINE (D4T) PLUS LAMIVUDINE (3TC) PLUS NEVIRAPINE (NVP) (PDF, 51K)

4.5. ABACVIR (ABC) PLUS ZIDOVUDINE (AZT) PLUS LAMIVUDINE (3TC) (PDF, 51K)

4.6. ABACVIR (ABC) PLUS LAMIVUDINE (3TC) (PDF, 49K)